These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31541588)

  • 1. Update on the efficacy and safety of sodium-glucose cotransporter 2 inhibitors in Asians and non-Asians.
    Fujita Y; Inagaki N
    J Diabetes Investig; 2019 Nov; 10(6):1408-1410. PubMed ID: 31541588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-Glucose Cotransporter 2 Inhibitors and Fournier Gangrene: A Rare and Lethal Adverse Event.
    O'Malley PA
    Clin Nurse Spec; 2019; 33(2):63-65. PubMed ID: 30730449
    [No Abstract]   [Full Text] [Related]  

  • 3. Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations.
    Milder DA; Milder TY; Kam PCA
    Anaesthesia; 2018 Aug; 73(8):1008-1018. PubMed ID: 29529345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India.
    Ghosh A; Gupta R; Misra A
    J Diabetes; 2016 Sep; 8(5):738-9. PubMed ID: 27085074
    [No Abstract]   [Full Text] [Related]  

  • 5. Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype.
    Lim LL; Tan AT; Moses K; Rajadhyaksha V; Chan SP
    J Diabetes Complications; 2017 Feb; 31(2):494-503. PubMed ID: 27866701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.
    Kaku K; Watada H; Iwamoto Y; Utsunomiya K; Terauchi Y; Tobe K; Tanizawa Y; Araki E; Ueda M; Suganami H; Watanabe D;
    Cardiovasc Diabetol; 2014 Mar; 13():65. PubMed ID: 24678906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison chart: SGLT2 inhibitors.
    Med Lett Drugs Ther; 2020 Nov; 62(1611):e2-e4. PubMed ID: 33429417
    [No Abstract]   [Full Text] [Related]  

  • 8. Differentiating Among the SGLT-2 Inhibitors: Considering Cardiovascular and Other Safety Outcomes.
    Miller EM; Wysham CH
    J Fam Pract; 2018 Aug; 67(8 suppl):S37-S42. PubMed ID: 30137052
    [No Abstract]   [Full Text] [Related]  

  • 9. Euglycemic Ketoacidosis Caused by Sodium-Glucose Cotransporter 2 Inhibitors: A Case Report.
    Bobart SA; Gleason B; Martinez N; Norris K; Williams SF
    Ann Intern Med; 2016 Oct; 165(7):530-532. PubMed ID: 27699391
    [No Abstract]   [Full Text] [Related]  

  • 10. Considerations for SGLT2 inhibitor use in post-transplantation diabetes.
    Hecking M; Jenssen T
    Nat Rev Nephrol; 2019 Sep; 15(9):525-526. PubMed ID: 31235880
    [No Abstract]   [Full Text] [Related]  

  • 11. Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes.
    Peacock SC; Lovshin JA; Cherney DZI
    Anesth Analg; 2018 Feb; 126(2):699-704. PubMed ID: 28786838
    [No Abstract]   [Full Text] [Related]  

  • 12. Dapagliflozin-Associated Diabetic Ketoacidosis.
    Chakinala RC; Chang AP; Solanki S; Haq KF; Cho R
    Am J Ther; 2018; 25(6):e765-e766. PubMed ID: 29672334
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
    Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
    Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In brief: ketoacidosis with SGLT2 inhibitors.
    Med Lett Drugs Ther; 2015 Jun; 57(1471):94. PubMed ID: 26079766
    [No Abstract]   [Full Text] [Related]  

  • 15. Two alcoholic liver cirrhosis patients developed diabetic ketoacidosis after SGLT2 inhibitors-prescription.
    Chao HY; Kornelius E
    J Formos Med Assoc; 2020 Dec; 119(12):1886-1887. PubMed ID: 32690358
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
    Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
    [No Abstract]   [Full Text] [Related]  

  • 17. Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication.
    Bloomgarden Z; Handelsman Y
    J Diabetes; 2020 Jan; 12(1):8-9. PubMed ID: 31722441
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible association between diabetic ketoacidosis and use of sodium-glucose co-transporter 2 inhibitor in a 17-year-old youth with type 2 diabetes.
    Shamchuk A; Doulla M; Jetha M
    CMAJ; 2021 Sep; 193(35):E1385-E1388. PubMed ID: 34493565
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical Adverse Events of High-Dose vs Low-Dose Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of 51 Randomized Clinical Trials.
    Shi FH; Li H; Yue J; Jiang YH; Gu ZC; Ma J; Lin HW
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32841351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.